Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Martin Cannon

Concepts (299)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Dendritic Cells
26
2023
133
3.770
Why?
Ovarian Neoplasms
23
2023
450
3.750
Why?
Cancer Vaccines
13
2020
78
3.030
Why?
Immunotherapy
12
2019
235
1.940
Why?
Th17 Cells
3
2020
25
1.520
Why?
Antigens, Neoplasm
11
2019
146
1.340
Why?
CD4-Positive T-Lymphocytes
8
2023
157
1.080
Why?
Uterine Cervical Neoplasms
13
2011
276
0.970
Why?
Oncogene Proteins, Viral
7
2011
52
0.820
Why?
Neoplasm Recurrence, Local
3
2020
626
0.770
Why?
T-Lymphocytes, Regulatory
6
2011
82
0.740
Why?
T-Lymphocytes, Cytotoxic
12
2013
65
0.710
Why?
Indoleamine-Pyrrole 2,3,-Dioxygenase
3
2014
16
0.660
Why?
Lymphocytes, Tumor-Infiltrating
4
2019
75
0.620
Why?
Neoplasms
4
2019
1233
0.570
Why?
CD8-Positive T-Lymphocytes
11
2023
124
0.570
Why?
Antibodies, Monoclonal
5
2019
457
0.560
Why?
DNA-Binding Proteins
5
2007
424
0.550
Why?
Interleukin-17
2
2020
37
0.540
Why?
p38 Mitogen-Activated Protein Kinases
2
2014
96
0.520
Why?
Ascites
1
2014
28
0.460
Why?
T-Lymphocytes
5
2017
328
0.450
Why?
Immunologic Surveillance
2
2011
10
0.450
Why?
Female
42
2023
26560
0.410
Why?
Cytokines
4
2014
607
0.410
Why?
Signal Transduction
3
2017
1608
0.410
Why?
Carcinoma
2
2017
139
0.400
Why?
T-Lymphocytes, Helper-Inducer
2
2011
42
0.380
Why?
Immunotherapy, Active
1
2011
4
0.380
Why?
Serine Endopeptidases
3
2009
51
0.380
Why?
Cytotoxicity, Immunologic
7
2011
56
0.370
Why?
Humans
53
2023
49898
0.370
Why?
Adoptive Transfer
1
2009
30
0.330
Why?
Immunotherapy, Adoptive
3
2005
158
0.320
Why?
Interferon-gamma
7
2020
176
0.310
Why?
Epitopes, T-Lymphocyte
3
2008
25
0.300
Why?
Lymphocyte Activation
3
2005
171
0.280
Why?
Adjuvants, Immunologic
3
2011
51
0.280
Why?
Papillomavirus Vaccines
1
2007
67
0.270
Why?
Herpesvirus 4, Human
2
2005
39
0.270
Why?
Immunodominant Epitopes
2
2008
8
0.270
Why?
Cell Line, Tumor
13
2022
1388
0.270
Why?
Animals
16
2023
13100
0.260
Why?
Dependovirus
3
2011
103
0.240
Why?
HLA-A2 Antigen
3
2009
11
0.220
Why?
Cell Transformation, Viral
1
2003
25
0.210
Why?
Cell Line, Transformed
1
2003
73
0.210
Why?
Poxviridae Infections
1
2022
4
0.210
Why?
Poxviridae
1
2022
7
0.210
Why?
Myxoma virus
1
2022
14
0.210
Why?
Oncolytic Virotherapy
1
2022
18
0.210
Why?
Interferon Type I
1
2022
24
0.200
Why?
Cystadenocarcinoma, Serous
5
2009
71
0.200
Why?
Vaccination
4
2010
275
0.200
Why?
Receptor, erbB-2
4
2008
74
0.200
Why?
Papillomavirus E7 Proteins
5
2011
31
0.200
Why?
Disease-Free Survival
2
2020
450
0.200
Why?
Interleukin-10
2
2017
83
0.190
Why?
Genes, MHC Class I
3
2008
11
0.190
Why?
Testis
2
2011
65
0.180
Why?
Membrane Proteins
4
2011
347
0.180
Why?
Injections, Intradermal
1
2020
14
0.180
Why?
Macrophages
4
2022
361
0.180
Why?
Immunity, Humoral
1
2020
22
0.180
Why?
Coculture Techniques
3
2014
143
0.180
Why?
Flow Cytometry
8
2013
470
0.180
Why?
Folate Receptor 1
1
2020
25
0.180
Why?
Cell Movement
2
2019
245
0.180
Why?
Carcinoma, Hepatocellular
1
2022
194
0.170
Why?
Enzyme-Linked Immunosorbent Assay
2
2013
234
0.170
Why?
Mice
9
2023
5658
0.170
Why?
Carcinoma, Lewis Lung
1
2019
9
0.170
Why?
B-Lymphocytes
5
2017
175
0.170
Why?
Repressor Proteins
3
2011
149
0.170
Why?
Melanoma, Experimental
1
2019
40
0.160
Why?
Self Tolerance
1
2019
1
0.160
Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2019
1
0.160
Why?
Liver Neoplasms
1
2022
329
0.160
Why?
Aged
12
2020
9447
0.160
Why?
Transplantation, Autologous
1
2020
462
0.160
Why?
Cells, Cultured
6
2014
1587
0.150
Why?
Cytotoxicity Tests, Immunologic
4
2005
27
0.150
Why?
N-Acetylglucosaminyltransferases
1
2017
16
0.150
Why?
Programmed Cell Death 1 Receptor
1
2017
40
0.140
Why?
Middle Aged
16
2020
12285
0.140
Why?
HLA Antigens
4
2006
53
0.140
Why?
Receptors, Notch
1
2017
27
0.140
Why?
Human Umbilical Vein Endothelial Cells
2
2014
90
0.140
Why?
Neoplastic Stem Cells
1
2017
100
0.130
Why?
Carcinoma, Papillary
3
2005
49
0.130
Why?
Poliovirus Vaccine, Oral
2
2005
4
0.120
Why?
Adult
15
2011
13346
0.120
Why?
Genetic Vectors
3
2011
128
0.120
Why?
Poliovirus
2
2005
10
0.120
Why?
Neoplasm Proteins
1
2017
321
0.120
Why?
Clinical Trials, Phase I as Topic
1
2015
24
0.120
Why?
Adenocarcinoma
3
2004
401
0.120
Why?
Antigen Presentation
5
2009
25
0.120
Why?
Galectin 3
1
2014
14
0.120
Why?
Kallikreins
2
2005
18
0.120
Why?
Neoplasm Invasiveness
3
2017
268
0.120
Why?
Cystadenocarcinoma, Papillary
2
2005
14
0.110
Why?
Histocompatibility Antigens Class I
2
2005
44
0.110
Why?
Peptide Fragments
4
2009
207
0.110
Why?
Endometrial Neoplasms
2
2005
137
0.110
Why?
Uterine Neoplasms
2
2005
60
0.110
Why?
Papillomavirus Infections
3
2011
167
0.110
Why?
Mutation
1
2019
1292
0.110
Why?
Mice, Inbred C57BL
3
2017
1777
0.100
Why?
Intracellular Signaling Peptides and Proteins
2
2022
139
0.100
Why?
Lymphocytes
1
2013
154
0.100
Why?
Killer Cells, Natural
4
2005
107
0.100
Why?
Antigens, Viral
3
2007
43
0.100
Why?
V-Set Domain-Containing T-Cell Activation Inhibitor 1
1
2011
4
0.100
Why?
rho GTP-Binding Proteins
1
2011
6
0.100
Why?
Clonal Anergy
1
2011
13
0.100
Why?
A Kinase Anchor Proteins
1
2011
2
0.100
Why?
Calmodulin-Binding Proteins
1
2011
10
0.090
Why?
Drug Resistance, Neoplasm
5
2017
314
0.090
Why?
Antigen-Presenting Cells
1
2011
24
0.090
Why?
Antigens, Surface
1
2011
48
0.090
Why?
Human papillomavirus 16
1
2011
44
0.090
Why?
Antineoplastic Agents, Alkylating
1
2011
74
0.090
Why?
Uterine Cervical Dysplasia
1
2011
49
0.090
Why?
Immunity, Cellular
2
2008
69
0.090
Why?
Cyclophosphamide
1
2011
163
0.090
Why?
Prostate
1
2011
117
0.090
Why?
Diphosphonates
1
2011
90
0.090
Why?
Imidazoles
1
2011
128
0.090
Why?
Phenotype
1
2013
728
0.090
Why?
Gene Expression Regulation, Neoplastic
4
2011
824
0.090
Why?
Gene Expression Profiling
2
2005
1028
0.090
Why?
Papillomaviridae
3
2005
102
0.080
Why?
Neoplasm Staging
3
2007
749
0.080
Why?
K562 Cells
2
2008
41
0.080
Why?
Carrier Proteins
1
2011
302
0.080
Why?
Tumor Microenvironment
2
2023
221
0.080
Why?
CA-125 Antigen
1
2008
16
0.080
Why?
Immediate-Early Proteins
1
2008
19
0.080
Why?
Cytomegalovirus
1
2008
27
0.080
Why?
RNA, Messenger
4
2005
1099
0.080
Why?
Green Fluorescent Proteins
1
2008
92
0.080
Why?
Interleukin-4
2
2005
44
0.080
Why?
Antibody Formation
1
2007
51
0.070
Why?
Antibodies, Viral
1
2007
93
0.070
Why?
Prostatic Neoplasms
1
2011
391
0.070
Why?
Amino Acid Sequence
2
2005
579
0.070
Why?
RNA Interference
2
2017
178
0.070
Why?
Ovary
3
2017
114
0.070
Why?
Molecular Sequence Data
2
2005
799
0.070
Why?
Oligonucleotide Array Sequence Analysis
2
2005
409
0.070
Why?
Recombinant Proteins
1
2007
482
0.070
Why?
Hypersensitivity, Delayed
1
2005
19
0.060
Why?
Breast Neoplasms
3
2003
1183
0.060
Why?
Neoplasms, Squamous Cell
1
2005
7
0.060
Why?
Monocytes
2
2022
131
0.060
Why?
Electroporation
1
2005
18
0.060
Why?
Cell Line
4
2010
1010
0.060
Why?
Poliomyelitis
1
2005
5
0.060
Why?
Enterotoxins
1
2005
12
0.060
Why?
Gene Transfer Techniques
1
2005
38
0.060
Why?
Genes, erbB-2
1
2005
8
0.060
Why?
Interleukin-12
1
2005
29
0.060
Why?
Immunologic Memory
1
2005
29
0.060
Why?
Reverse Transcriptase Polymerase Chain Reaction
4
2008
579
0.060
Why?
Antigens, Heterophile
1
2005
1
0.060
Why?
Plasmodium falciparum
1
2005
19
0.060
Why?
Burkitt Lymphoma
1
2005
26
0.060
Why?
Malaria, Falciparum
1
2005
14
0.060
Why?
Endemic Diseases
1
2005
22
0.060
Why?
Epstein-Barr Virus Infections
1
2005
29
0.060
Why?
Gangliosides
1
2004
5
0.060
Why?
Ascitic Fluid
1
2004
12
0.060
Why?
Proteins
2
2005
347
0.060
Why?
Genetic Therapy
1
2005
117
0.060
Why?
Ovariectomy
1
2004
113
0.060
Why?
Vaccines, Subunit
1
2004
15
0.060
Why?
Hysterectomy
1
2004
88
0.060
Why?
Immunization, Passive
1
2004
28
0.060
Why?
Clinical Trials as Topic
2
2007
466
0.060
Why?
Interleukin-6
1
2005
265
0.060
Why?
Tumor Necrosis Factor-alpha
2
2019
388
0.060
Why?
Cell Differentiation
2
2004
649
0.060
Why?
Protein Binding
1
2005
656
0.050
Why?
Epithelial Cells
1
2005
209
0.050
Why?
Vesiculovirus
1
2022
6
0.050
Why?
Virus Latency
1
2003
51
0.050
Why?
Vaccinia virus
1
2022
6
0.050
Why?
Host Specificity
1
2022
5
0.050
Why?
Cell Adhesion Molecules
1
2003
87
0.050
Why?
Cell Communication
1
2003
69
0.050
Why?
Nucleotidyltransferases
1
2022
13
0.050
Why?
Mammals
1
2022
57
0.050
Why?
Disease Models, Animal
2
2022
1411
0.050
Why?
Tumor Cells, Cultured
4
2003
462
0.050
Why?
Xenograft Model Antitumor Assays
2
2017
212
0.050
Why?
Disease Progression
2
2019
820
0.050
Why?
Radiotherapy
1
2002
124
0.050
Why?
Rabbits
1
2022
375
0.050
Why?
Down-Regulation
1
2003
342
0.050
Why?
Blood Transfusion
1
2002
125
0.050
Why?
Viral Proteins
1
2022
156
0.050
Why?
Immunohistochemistry
4
2005
972
0.040
Why?
Carcinoma, Squamous Cell
1
2004
330
0.040
Why?
Transcriptome
1
2022
312
0.040
Why?
Endothelium
1
2019
37
0.040
Why?
Intercellular Adhesion Molecule-1
1
2019
61
0.040
Why?
Gene Expression
3
2008
612
0.040
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2004
994
0.040
Why?
Injections, Intraperitoneal
2
2010
54
0.040
Why?
Tissue Banks
1
2017
8
0.040
Why?
Antibodies, Monoclonal, Humanized
3
2004
223
0.040
Why?
Mice, Inbred NOD
1
2017
94
0.040
Why?
STAT3 Transcription Factor
1
2017
80
0.040
Why?
Glycosylation
1
2017
102
0.040
Why?
Tumor Burden
1
2017
131
0.040
Why?
RNA, Small Interfering
1
2017
210
0.040
Why?
Multiple Myeloma
1
2011
2915
0.030
Why?
Protein Processing, Post-Translational
1
2017
154
0.030
Why?
Lung Neoplasms
1
2002
600
0.030
Why?
Kaplan-Meier Estimate
1
2017
463
0.030
Why?
Survival Analysis
2
2010
670
0.030
Why?
Apoptosis
2
2014
1092
0.030
Why?
Pore Forming Cytotoxic Proteins
2
2005
9
0.030
Why?
Perforin
2
2005
11
0.030
Why?
Anti-Bacterial Agents
1
2019
742
0.030
Why?
Neovascularization, Pathologic
1
2014
153
0.030
Why?
Interleukin-2
2
2003
70
0.030
Why?
Membrane Glycoproteins
2
2005
244
0.030
Why?
Vaginal Smears
1
2011
28
0.020
Why?
Organ Specificity
1
2011
106
0.020
Why?
Prostate-Specific Antigen
1
2011
47
0.020
Why?
DNA, Viral
1
2011
133
0.020
Why?
Time Factors
2
2010
2891
0.020
Why?
Major Histocompatibility Complex
1
2010
12
0.020
Why?
Prognosis
2
2005
1956
0.020
Why?
Transduction, Genetic
1
2008
45
0.020
Why?
Fluorescent Antibody Technique
1
2008
112
0.020
Why?
Leukocytes, Mononuclear
1
2008
112
0.020
Why?
Alphapapillomavirus
1
2007
13
0.020
Why?
T-Lymphocyte Subsets
1
2007
38
0.020
Why?
Models, Immunological
1
2007
8
0.020
Why?
Aged, 80 and over
2
2005
3136
0.020
Why?
Immune Tolerance
1
2007
84
0.020
Why?
Adolescent
2
2011
6414
0.020
Why?
HLA-B Antigens
1
2006
7
0.020
Why?
Clone Cells
1
2006
78
0.020
Why?
Immunity, Innate
1
2007
104
0.020
Why?
Male
3
2011
25437
0.020
Why?
Claudin-3
1
2005
5
0.020
Why?
Claudin-4
1
2005
7
0.020
Why?
Combined Modality Therapy
1
2007
638
0.020
Why?
Mice, Inbred C3H
1
2005
82
0.020
Why?
Peptides
1
2006
220
0.020
Why?
Protein Sorting Signals
1
2005
10
0.020
Why?
Protein Engineering
1
2005
18
0.020
Why?
Histocompatibility Antigens Class II
1
2005
37
0.020
Why?
Mice, SCID
1
2005
173
0.020
Why?
Species Specificity
1
2005
193
0.020
Why?
Plasmids
1
2005
164
0.020
Why?
Protein Folding
1
2005
48
0.020
Why?
Epithelium
1
2004
65
0.010
Why?
Endocytosis
1
2005
61
0.010
Why?
Carboplatin
1
2004
51
0.010
Why?
Receptors, Cell Surface
1
2005
120
0.010
Why?
Radiotherapy, Adjuvant
1
2004
60
0.010
Why?
Paclitaxel
1
2004
83
0.010
Why?
Transfection
1
2005
354
0.010
Why?
Antineoplastic Agents, Hormonal
1
2004
49
0.010
Why?
Polymerase Chain Reaction
1
2005
456
0.010
Why?
Antibody-Dependent Cell Cytotoxicity
1
2003
12
0.010
Why?
Tumor Stem Cell Assay
1
2003
17
0.010
Why?
Proportional Hazards Models
1
2005
404
0.010
Why?
Cervix Uteri
1
2004
42
0.010
Why?
Swine
1
2005
396
0.010
Why?
Up-Regulation
1
2005
446
0.010
Why?
Kinetics
1
2005
632
0.010
Why?
Keratinocytes
1
2004
90
0.010
Why?
Receptors, Interleukin-2
1
2002
7
0.010
Why?
Lymphocyte Subsets
1
2002
13
0.010
Why?
Leukocytes
1
2003
66
0.010
Why?
Receptors, Antigen, T-Cell
1
2003
49
0.010
Why?
Cell Culture Techniques
1
2003
97
0.010
Why?
Antigens, CD19
1
2002
26
0.010
Why?
Receptors, IgG
1
2002
22
0.010
Why?
Cell Death
1
2003
174
0.010
Why?
Doxorubicin
1
2004
233
0.010
Why?
Immunophenotyping
1
2002
109
0.010
Why?
Cisplatin
1
2004
275
0.010
Why?
Survival Rate
1
2005
905
0.010
Why?
Tumor Virus Infections
1
2002
46
0.010
Why?
Antibodies, Monoclonal, Murine-Derived
1
2002
47
0.010
Why?
Young Adult
1
2011
4029
0.010
Why?
Fatal Outcome
1
2002
194
0.010
Why?
Cell Division
1
2002
294
0.010
Why?
Case-Control Studies
1
2004
1128
0.010
Why?
Prospective Studies
1
2004
2345
0.010
Why?
Risk Factors
1
2004
3604
0.010
Why?
Antineoplastic Agents
1
2002
1175
0.010
Why?
Cannon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description